Klein, John M
For individuals with obesity-related health conditions such as type 2 diabetes, PCOS, high blood pressure, cardiovascular disease, or non-alcoholic fatty liver disease (NAFLD), weight management therapies such as GLP-1s can be an essential component of comprehensive treatment plans aimed at reducing disease and improving overall health
The CPHA article identifies semaglutide products as Ozempic, Wegovy, and Rybelsus, and lists tirzepatide as Mounjaro
Based on publicly reported data from 2019 and 2023, 10 common diabetes prescriptions (mostly GLP1 drugs) under Medicare Part D grew by over 300%, 6 while the diabetic population only increased modestly
A meta-analysis of naltrexone on alcohol self-administration and craving found reliable reductions in how much people drank and how strongly they craved
This steady motivation makes it easier to maintain long-term weight-loss habits